Clinical Trials · NCT04012918

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

Name: Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Unknown
Sponsor: Ain Shams University
Enrollment: 124
Start date: Aug 2018
Locations: 1 site, Egypt
Primary endpoint: Progress-free survival

View Gonadorelin compound reference